The Trump administration reclassified medical marijuana as a less dangerous drug on Thursday. FDA-approved and state-licensed medical marijuana was rescheduled from a Schedule I drug to the less strict Schedule III category. Irwin Simon, the chairman and CEO of Tilray, joined “Forbes Newsroom” to react to the news, and discuss what it means for the cannabis industry.
